Results 121 to 130 of about 6,317 (201)

Using biomarkers and independent predictors of therapy response to optimize treatment of uncontrolled severe asthma in the biologic era. [PDF]

Front Allergy
Yasui H.
europepmc   +1 more source

Benralizumab for adults with rare and off-label eosinophilic disorders: a 52-week prospective, single-center study. [PDF]

Front Immunol
Talmon A, Shamriz O, Rubin L, Ribak Y, Aynor I, Nevo A, Elia A, Sion MB, Forkosh E, Hershko AY, Tal Y.   +10 more
europepmc   +1 more source

Real-World Safety and Effectiveness of Benralizumab in Japanese Patients with Severe Asthma: A Multicenter Prospective Observational Study

Journal of Asthma and Allergy
Masao Yamaguchi,1 Yoshihiro Nishimura,2 Yuko Takumi,3 Nobuya Hayashi,4 Kei Sakamoto,3 Yuji Tohda5 1Division of Respiratory Medicine, Third Department of Medicine, Teikyo University Chiba Medical Center, Ichihara, Chiba, Japan; 2Kita-Harima Medical Center,
Yamaguchi M, Nishimura Y, Takumi Y, Hayashi N, Sakamoto K, Tohda Y   +5 more
doaj  

COPD 2.0: Bronchodilators, biologics and beyond - A systematic review. [PDF]

Lung India
Shamim H, Singh AK, Sharma R, Mishra RK.
europepmc   +1 more source

Coronary Vasospasm in Eosinophilic Granulomatosis With Polyangiitis Presenting as Acute Coronary Syndrome Treated With Anti-IL-5. [PDF]

JACC Case Rep
Thota P, Sharma S, Mohammed U.
europepmc   +1 more source

ORBE II Study: Clinical Characteristics and Outcomes After Treatment with Benralizumab According to Airflow Obstruction Status and Smoking Habit. [PDF]

J Clin Med
Martínez-Rivera C, Blanco-Aparicio M, Casas-Maldonado F, Sánchez-Toril López F, Palop-Cervera M, Cassini LF, Sanchez-Trincado JL, Luzon E, Nuevo J, Secall L, González-Sierra M, Barragán CP, Padilla-Galo A.   +12 more
europepmc   +1 more source

Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A 32-Week Evaluation.

Int Arch Allergy Immunol
Özden Ş, Tepetam FM, Bozkurt Y, Terzioğlu Şahin F, Aynacı A, Avcı HF, Dursun M, Demirkol MA, Yildirim N.   +8 more
europepmc   +1 more source

Recent Developments in Monoclonal-Antibody-Based Biologic Therapy for Severe Refractory Eosinophilic Asthma. [PDF]

Antibodies (Basel)
Walsh GM.
europepmc   +1 more source

Clinical outcomes after switching from omalizumab to anti-IL-5/IL-5R biologics in severe asthma: a retrospective cohort study. [PDF]

BMC Pulm Med
Akkuş FA, Çölkesen F, Önalan T, Gerek ME, Kılınç M, Arslan Ş.   +5 more
europepmc   +1 more source

Psychological and Related Factors Influencing Adherence to Biologic Therapies in Asthma: A Scoping Review. [PDF]

Curr Allergy Asthma Rep
Poletti V, Volpato E.
europepmc   +1 more source